Following publication of our two articles [ 1 , 2 ], a critique of the methodology of Phenotype-Genotype Many-to-Many Relations Analysis (PGMRA) [ 1 , 3 , 4 ] questioned the validity of our results from the perspective of polygenic risk scores (PRS) [ 5 ]. We appreciate the importance of these questions, and here provide a concise discussion of the assumptions and mathematical constraints of both approaches. We thank this commentator and others who have discussed our articles with us for their thoughtful questions and critiques.
No takes yet. Share an insight, caveat, or question.
Zwir et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: